Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS® (apixaban)

Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS ® (apixaban)

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYS: BMY) and Pfizer Inc. (NYS: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved ELIQUIS® (apixaban).

Please see full Prescribing Information including BOXED WARNING and Medication Guide available at www.bms.com .


Bristol-Myers Squibb and Pfizer will provide additional information on the FDA approval of Eliquis in a separate press release, to be issued next week.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

anImage


Bristol-Myers Squibb
Media:
Laura Hortas, 609-240-7025
Laura.hortas@bms.com
or
Investors:
Ranya Dajani, 609-252-5330
Ranya.Dajani@bms.com
or
Ryan Asay, 609-252-5020
Ryan.Asay@bms.com
or
Pfizer Inc.
Media:
MacKay Jimeson, 212-733-2324
MacKay.Jimeson@pfizer.com
or
Investors:
Suzanne Harnett, 212-733-8009
Suzanne.Harnett@pfizer.com

KEYWORDS:   United States  North America  New Jersey  New York

INDUSTRY KEYWORDS:

The article Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS® (apixaban) originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Introduction to Economic Indicators

Measure the performance of the economy.

View Course »

Finding Stock Ideas

Learn to do your research and find investments.

View Course »

Add a Comment

*0 / 3000 Character Maximum